Takeda Pharmaceutical (TAK) Change in Accured Expenses (2020 - 2025)

Takeda Pharmaceutical has reported Change in Accured Expenses for 6 years, with the latest figure at -$121.2 million in Q2 2025.

• On a quarterly basis, Change in Accured Expenses fell 310.4% year-over-year to -$121.2 million in Q2 2025; TTM through Jun 2025 was -$206.5 million, a 175.03% decrease from a year earlier, with the FY2025 full-year figure at -$22.9 million, up 82.22% from the prior year.
• Change in Accured Expenses was -$121.2 million for Q2 2025 at Takeda Pharmaceutical, down from $40.0 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.4 billion in Q1 2021, with the low at -$459.0 million in Q4 2021.
• Average Change in Accured Expenses over 5 years is $48.8 million, with a median of $26.7 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2023: Change in Accured Expenses tumbled 1245.26% in 2021, then surged 317.94% in 2023.
• Over 5 years, Change in Accured Expenses stood at -$459.0 million in 2021, then soared by 93.82% to -$28.4 million in 2022, then surged by 317.94% to $61.8 million in 2023, then fell by 16.34% to $51.7 million in 2024, then tumbled by 334.37% to -$121.2 million in 2025.
• The last three Change in Accured Expenses figures came in at -$121.2 million (Q2 2025), $40.0 million (Q1 2025), and $51.7 million (Q4 2024), per Business Quant data.